Investor Relations

Headquartered in Cambridge, Mass., Magenta Therapeutics (Nasdaq:MGTA) is a clinical-stage biotechnology company developing therapeutics to reset the immune system in order to cure more patients with devastating and life-threatening diseases. This immune reset approach can be applied through stem cell transplant to multiple diseases, including blood cancers, such as acute myeloid leukemia; genetic diseases, such as sickle cell disease; and autoimmune diseases, such as multiple sclerosis and systematic sclerosis.

Magenta’s comprehensive approach to precision immune system reset will transform many aspects of the transplant process, aiming to make it more effective and safer.